Curis, Inc.
CRISHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeCuris, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Valued at $937K, CRIS is a micro-cap name in its sector. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma.
Market Cap
$936,807
Beta
3.10
P/E (TTM)
0.29
P/E (Fwd)
-0.06
EPS (TTM)
$1.32
EPS (Fwd)
$-6.01
ROE
—
ROA
-93.2%
Cash
$5.1M
Total Debt
$1.0M
Free CF
-$15.8M
52W Change
-98.8%
Annual Financials
Cash vs Debt
Where CRIS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CRIS finished 94.21% below its 150-day moving average ($6.56) and 96.14% below its 200-day moving average ($9.84). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CRIS overbought or oversold?
At the October 20, 2026 close, CRIS's RSI(14) was 2.1, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $5.1M in cash comfortably exceeding the $1.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$15.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has been relatively flat, moving from $10.2M (2022) to $9.4M (2025).
A beta of 3.10 means CRIS is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, CRIS has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Curis, Inc.'s trajectory.